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Objective. Electronic clinical quality measures (eCQMs) are increasingly used by health registries and third parties to eval-
uate and improve the quality of health care. To complete these eCQMs, data are extracted from electronic health records
(EHRs). The treatment of gout has been an area identified with gaps in quality of care. On behalf of the American College of
Rheumatology (ACR), we sought to develop and test eCQMs to evaluate gout care.
Methods. Drawing from the 2012 ACR gout guidelines, a working group developed candidate gout process measures that
were evaluated by an interdisciplinary panel of health care stakeholders, the ACR Quality Measures Subcommittee (QMS),
and ultimately the ACR Board of Directors for formal validity testing. For each of the selected gout eCQMs, 3 clinical sites
using different EHR systems tested the scientific feasibility and validity of the measures. Measures appropriate for account-
ability were presented for national endorsement.
Results. Of the 10 proposed eCQMs, 4 were endorsed by the ACR QMS, 3 were incorporated into the ACR’s Rheumatology
Informatics System for Effectiveness (RISE) Registry, and 2 were endorsed by the National Quality Forum. The 3 eCQMs
incorporated into RISE (evaluating indications for urate-lowering therapy [ULT]), monitoring serum urate, and treat-to-tar-
get outcome) demonstrated high validity and reliability. Proportions of patients passing these 3 eCQMs in RISE and at the 3
clinical testing sites ranged between 32% and 58%, indicating significant room for improvement in care.
Conclusion. Three eCQMs have been validated and implemented into RISE. Two of these measures (evaluating indications
for ULT and monitoring serum urate) are available for use in federal quality reporting programs. Performance on these
measures suggests there is significant room for improvement in the management of gout.
INTRODUCTION
In response to national quality measurement initiatives,
the American College of Rheumatology (ACR) developed
a quality measure (QM) development program (1). Cur-
rent ACR QMs are derived from their respective ACR
guideline publications and have been published for
rheumatoid arthritis (2).
Gout affects 8.3 million US adults (3). Furthermore, sig-
nificant gaps in the quality of care for gout patients have
been described (4–11). These gaps persist despite multiple
international educational attempts through guideline
development to improve care for patients with gout (12–
18). Given the prevalence of gout and the persistence of
gaps in care despite recent guidelines, gout was selected
as an ideal target condition for the development of QMs.
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To develop gout QMs, the ACR Board of Directors and
ACR Committee on Quality of Care tasked the ACR Qual-
ity Measures Subcommittee (QMS) to develop electroni-
cally specified clinical quality measures (eCQMs) for
gout (19) that can be implemented using electronic
health records (EHRs). The ACR QMS then formed a
committee of gout specialists (Gout QM Working Group)
to develop the eCQMs (for working group composition
and disclosures, see Supplementary Appendix A, avail-
able on the Arthritis Care & Research web site at http://
onlinelibrary.wiley.com/doi/10.1002/acr.23500/abstract).
The purpose of this article is to describe the development,
testing, and evaluation of ACR gout eCQMs.
METHODS
As per prior methodology (2), the ACR instructed the Gout
QMWorking Group to develop eCQMs based upon the 2012
ACR gout guidelines (16,17) as outlined in Figure 1. In brief,
the working group developed the eCQMs as “If. . .then. . .be-
cause. . .” statements. In general terms, IF a condition exists,
THEN an intervention should be done, BECAUSE the evi-
dence shows that the intervention will improve patient out-
comes. The eCQMs described here are appropriate for
patients with clinical gout, not patients with asymptomatic
hyperuricemia.
After evaluating gaps in quality of care, the availability
of existing gout QMs, and strength of evidence for various
recommendations in the 2012 ACR gout guidelines, the
working group developed an extensive list of candidate
eCQMs for consideration. Through a series of teleconfer-
ences, the working group iteratively refined and internally
ranked the candidate eCQMs for importance and
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Figure 1. Overview of the American College of Rheumatology (ACR) gout electronic clinical quality measure development.
Significance & Innovations
• Three electronic clinical quality measures for
gout have been developed by the American Col-
lege of Rheumatology and validated for use with
electronic health records.
• Performance on these measures suggests that there is
room for improvement in the management of gout.
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feasibility. The working group submitted the top 10 candi-
date eCQMs with the highest internal rankings to an inde-
pendent, multidisciplinary task force panel (TFP)
convened to rate these measures using the RAND/UCLA
Appropriateness Method (20) (for further information,
including detailed disclosures, see Supplementary
Appendix A, available on the Arthritis Care & Research
web site at http://onlinelibrary.wiley.com/doi/10.1002/acr.
23500/abstract).
The gout TFP was composed of 5 academic and 4 commu-
nity physicians representing the following specialties: rheu-
matology (n = 4), internal medicine (n = 3), geriatrics (n = 1),
and nephrology (n = 1). Additionally, there was 1 patient rep-
resentative and 1 third-party payer (insurance industry) repre-
sentative. The TFP moderator was an internist with several
years of experience moderating UCLA/RAND consensus
meetings (including moderating the consensus meeting for
the original ACR 2012 gout guidelines process). Less than
45% of the group had potential conflicts of interest. Three of
the 12 TFP members and the moderator were coauthors from
the 2012 ACR gout guidelines.
The TFP convened by webinar on November 8, 2013 to
discuss results from the first round of voting. Where varia-
tion in opinion existed, using a Delphi consensus method-
ology (20), the panel discussed disagreements and then re-
voted to reach a final consensus position for each eCQM.
The TFP endorsed all 10 candidate eCQMs, which the ACR
posted online for public comment between February 1 and
February 25, 2014. The working group members reviewed
the 14 public comments. The working group modified mea-
sure (M) 9: allopurinol starting dose in response to public
comment (changing the recommended starting dose; see
Table 1 for details) and returned the modified measure to
the TFP for re-voting.
The TFP and working group then jointly ranked the
endorsed eCQMs using a 1–9 scale for a single summary
score, incorporating measure importance, feasibility, and
validity. The ACR QMS reviewed each eCQM, its summary
score, and perceived feasibility to select eCQMs to advance
to field testing for the purpose of formal validity and reli-
ability testing (2). To recruit 3 clinical sites for field testing,
the ACR staff sent an e-mail solicitation to all ACR members
describing the methodology. From the 6 sites that responded
to the solicitation, the ACR staff selected 3 sites with an
EHR system and geographic diversity (2 sites withdrew their
submission after reviewing details of the work request, and
1 site was not able to get internal review board approval.
See Acknowledgments for details on participating sites,
type of EHR, and local investigators). As described by
Yazdany et al (2), each site, using an automated abstraction
program, abstracted cases that met the denominator definition
(for each measure) from the EHR and scored each case as
pass, fail, or excluded (if exclusion criteria were present).
The American Medical Association–convened Physician
Consortium for Performance Improvement, functioning as
an external consulting agency (with experience validating
QMs), determined the number of cases per QM per site to be
manually abstracted. Those cases were then randomly sam-
pled from the full sample of cases from each site that had
met the case denominator definition. At each site, for each
QM, a physician manually abstracted the data and coded the
selected case as pass, fail, or excluded (where exclusion cri-
teria were present). Agreement between manually abstracted
results and the automated abstraction were compared by cal-
culating percent agreement and kappa scores.
The eCQMs selected by the QMS were incorporated into
the ACR’s Rheumatology Informatics System for Effectiveness
(RISE) Registry (21), a clinical data registry developed by the
ACR with the goal of helping rheumatologists adapt to evolv-
ing regulatory changes in the era of “pay-for-performance.”
RESULTS
Below we list the 10 eCQMs developed by the working
group and submitted to the TFP for review, organized by
areas of care: management of acute gouty arthritis (M1),
urate-lowering therapy (ULT) (M2–M9), and prophylaxis
against acute gout attacks (M10). All 10 eCQMs were
reviewed favorably by the TFP. Three eCQMs (M2, M4,
and M10) and 1 hybrid eCQM (M7 and M8 combined
into a single eCQM) were approved by QMS for field
testing and submission to the National Quality Forum
(NQF). Two eCQMs (M2 and M7/8) addressing “indica-
tions for ULT” and “treat-to-target” objectives were given
NQF eMeasure Trial Approval status (NQF 2550 and
NQF 2549, respectively), which supports eCQMs under-
going reliability and validity testing (22). These 2 eCQMs
(M2 and M7/8) with M4, addressing serum urate (sUA)
surveillance after starting or changing ULT, were incor-
porated into RISE beginning January 2016 and completed
field testing (described below) to evaluate reliability and
validity as specified by the NQF.
For all of the eCQMs, we list the title, the “if. . .then. . .be-
cause. . .” statement, a brief background, and measure status
with respect to the TFP, QMS, RISE, and the NQF. For mea-
sures submitted by the QMS for field testing (M2, M4, and
M7/M8), literature supporting the measure is included
below; literature supporting the other measures is provided
in Supplementary Appendix B (available on the Arthritis
Care & Research web site at http://onlinelibrary.wiley.com/
doi/10.1002/acr.23500/abstract). On the measure title line,
endorsement status (TFP, QMS, or NQF) or adoption into
RISE is denoted in parentheses (TFP, QMS, NQF, or RISE)
where applicable.
Gout flare management
Measure 1: colchicine dosing (TFP endorsed). “IF a
patient receives colchicine for treatment of gout, THEN
the dose of colchicine should not exceed 2.4 mg in any
24-hour period, BECAUSE higher doses of colchicine are
associated with increased risk of adverse drug events and
do not provide additional therapeutic benefit.”
Of the potential recommendations on the management of
gout flares, the working group focused on low-dose colchi-
cine dosing regimens as an area that would benefit from a
quality improvement measure. Originally conceived to
directly address the loading dose of colchicine, the group
felt that identification of loading doses by medical record
abstraction would be impractical, and therefore the simpler
definition of a maximum daily dose was recommended.
Recent American College of Physicians (ACP) clinical
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practice guidelines for the management of acute and recur-
rent gout also recommended using low-dose colchicine
(23).
Measure status. Although endorsed by the TFP, the
eCQM was ranked in a tie for eighth highest, with concerns
about the ability to accurately abstract drug use and dose
using current EHR technology. This measure was not ad-
vanced to field testing, or incorporated into the ACR RISE
registry, nor submitted to the NQF for consideration due to
these feasibility concerns.
Management of ULT
The majority of the eCQMs focus on the use of ULT. Derived
from the ACR gout guidelines (16), the conceptual strategy
for managing patients requiring ULT is summarized in Fig-
ure 2. The eCQMs in this group cover indications for start-
ing ULT (M2), and, once a patient is on ULT, parameters for
monitoring therapy (M4, M5, and M7), with more frequent
monitoring dependent upon symptom activity and condi-
tional treatment responses based on sUA values (M6). The
underlying strategy to the ULT algorithm is “treat-to-target,”
with a specific eCQM mandating reaching target, defined as
sUA <6.8 mg/dl after 12 months of ULT (M8). More detailed
discussion for each eCQM follows below, including the
decision to combine M7 and M8 and the rationale for an
sUA target of 6.8 mg/dl.
Measure 2: indications for ULT (TFP, QMS, NQF en-
dorsed, RISE incorporated). Logically, identifying gout
patients with hyperuricemia and in need of ULT is the first
step in managing gout. M2 specifies this objective. “IF a pa-
tient with gout has sUA >6 mg/dl and has 1 of the following:
tophus/tophi or 2 or more attacks per year, THEN ULT
should be prescribed, BECAUSE such therapy will improve
sUA levels, decrease the risk for recurrent attacks and reduce
tophus deposition.”
The ACR gout treatment guidelines specify that patients
with 2 or more gout attacks/year, tophi, or radiographic
erosions specific for gout should be started on ULT (16).
The European League Against Rheumatism (EULAR)
developed a similar recommendation in its gout treatment
guidelines (14) and the subsequent 2016 update (18). A
similar measure concept was previously proposed by clin-
ical experts (24). The 2016 EULAR guideline update
included additional conditions for treatment after an ini-
tial flare, including “. . .a young age (<40 years) or with a
very high sUA level (>8.0 mg/dl; 480 lmoles/liter) and/or
comorbidities (renal impairment, hypertension, ischemic
heart disease, heart failure)” (18).
Figure 2. Conceptual model for management of urate-lowering therapy (ULT) in gout management. Measure (M) 2 = indications for ULT;
M4 = serum urate (sUA) surveillance after start or change in ULT; M5 = sUA surveillance for patients with ongoing symptoms or tophi;
M6 = optimize ULT; M7 = sUA surveillance for all patients on ULT, regardless of symptoms; M8 = sUA target for all patients on ULT.
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There is extensive literature on the benefits of ULT for gout
patients with active disease, specifically, reduced symptoms
and morbidity (25–29). Gout patients who have persistent
hyperuricemia are at risk of formation of urate deposits
(tophi), which can lead to joint and other tissue damage.
ULT is effective at improving outcomes in gout (both fre-
quency of attacks and tophus resolution). Various well-
designed cohort studies have shown that ULT reduces the
frequency of gout attacks (30–33), the rate of growth of gouty
tophi, and the size of tophi (25). In the Febuxostat Versus
Allopurinol Controlled Trial that included 762 patients with
gout and with sUA levels ≥8.0 mg/dl, ULT was associated
with reduction of sUA, tophi, and clinical gout flares (27).
Pegloticase studies have demonstrated that lowering of sUA
led to reduced frequency of gout flares (4–6 months after
treatment) (34), improved health-related quality of life, (35),
and reduction in tophus burden (36). In a recent randomized
trial, patients assigned to an intensive, nurse-led, treat-to-tar-
get intervention (versus standard of care) were more likely to
achieve sUA target (95% versus 29%), fewer gout flares dur-
ing the second year (0.33 versus 0.94 flares per year), and
reduction in tophi (2.6% versus 13.7%) (37).
Additional data supporting the impact of lowering sUA on
gout outcomes come from studies where patients taking
allopurinol were asked to either stop the medication or to
take it intermittently (38,39). Following complete cessation
of allopurinol by patients who had been well controlled
(years without gout attacks), one-third of patients had recur-
rent attacks after a mean followup of 86 weeks (39). In an
open-label extension study, 1,086 gout patients were treated
with fixed-dose daily ULT with febuxostat (80 mg or 120 mg)
or allopurinol (300 mg) to achieve sUA <6 mg/dl and mainte-
nance for up to 40 months (26). Maintenance of sUA <6 mg/
dl resulted in near absence of any gout flares requiring treat-
ment and tophus resolution in 29–46% of subjects (26). In
the Febuxostat Open-Label Clinical Trial of Urate-Lowering
Efficacy and Safety (FOCUS) study, a 5-year open-label
extension study, patients were treated with febuxostat 40–
120 mg/day (26). Patients had a sustained reduction of sUA,
nearly complete elimination of gout flares, and resolution of
tophi (26).
Measure status. M2 was endorsed by the TFP (mean
rating 8.6, on a 1–9 scale). This measure was further sup-
ported by the QMS for formal field testing and incorporation
into RISE. It was submitted to the NQF and given eMeasure
Trial Approval, with the condition that presence of gouty
erosions be dropped as an indication for ULT, citing lack of
direct data supporting use of radiographs as an indication for
ULT.
In field testing, the measure demonstrated excellent agree-
ment between automated EHR abstraction and physician chart
abstraction (Table 2), while site investigators reported that
identifying prior gout flares was challenging (denominator
specification). However, when cases were identified, the false
positive rate was zero. The proportion of patients meeting the
measure quality specification (use of ULT in active or topha-
ceous gout) was 58% (n = 96 cases) from the 3 clinical sites
and 56% (n = 515 cases) from the fourth quarter of 2015 in
RISE (Table 3). While this measure maymiss some denomina-
tor cases (in which a patient should be receiving ULT), testing
results support that it does not misidentify numerator cases,
and therefore still identifies an important performance gap
despite failing to capture all potential denominator cases.
Management of patients on ULT therapy
Once ULT is initiated, its use ought to be titrated until the
sUA target is achieved. There is extensive literature docu-
menting gaps in care, which include lack of monitoring the
efficacy of ULT medication, failure to assess adherence,
and lack of titration of ULT to achieve target (see Supple-
mentary Appendix B, available on the Arthritis Care &
Research web site at http://onlinelibrary.wiley.com/doi/10.
1002/acr.23500/abstract).
For patients taking ULT, eCQMs 3–7 address the neces-
sary steps of ULT administration to optimize clinical out-
comes (reduce gout flare frequency and tophus burden). The
rationale for these eCQMs is dependent upon the following
Table 2. Agreement between automated electronic health record abstraction and physician chart
abstraction*
Site 1 Site 2 Site 3 Overall
M2: Indications (n = 96)
Denominator 100 (1.0) 100 (1.0) 100 (1.0) 100 (1.0)
Numerator 100 (1.0) 100 (1.0) 100 (1.0) 100 (1.0)
Exclusions NA NA NA NA
Overall 100 (1.0) 100 (1.0) 100 (1.0) 100 (1.0)
M4: Serum urate monitoring (n = 197)
Denominator 100 (1.0) 90 (0.75) 85 (0)† 92 (0.60)
Numerator 92 (0.83) 100 (1.0) 93 (0.85) 95 (0.90)
Exclusions NA NA NA NA
Overall 92 (0.83) 76 (0.64) 86 (0.69) 85 (0.74)
M7/8: Serum urate target (n = 171)
Denominator 99 (0.83) 100 (1.0) 95 (0.83) 98 (0.91)
Numerator 96 (0.93) 90 (0.78) 96 (0.93) 95 (0.90)
Exclusions 100 (1.0) 98 (0.95) 98 (0.94) 100 (1.0)
Overall 96 (0.93) 90 (0.78) 100 (1.0) 96 (0.92)
* Values are the percent agreement (kappa). M = measure; NA = not applicable.
† Probability of random agreement equals observed agreement resulting in j = 0.
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tenets: 1) sUA is a valid intermediary for clinical outcomes
(14,15,18,30,34–36,40–43), 2) current ULT administration
(as measured by sUA outcome) is suboptimal (4–11), and 3)
improvement in the use of ULT and better sUA outcomes
will lead to improved patient quality of life through fewer
flares and limiting or preventing damage of tissues through
reduction of tophi (4,10,11,25,27,28,30–33,35,44–47). For
detailed discussion of the literature supporting these points,
please refer to Supplementary Appendix B, available on the
Arthritis Care & Research web site at http://onlinelibrary.
wiley.com/doi/10.1002/acr.23500/abstract.
Measure 3: uninterrupted ULT treatment (TFP endorsed)
“IF a patient has gout and receives ULT, THEN ULT should
be uninterrupted, BECAUSE interrupting ULT may cause
or exacerbate gout flare.”
The measure was initially conceived for use in either the
inpatient setting (to address the common misunderstanding
that ULT be held during a gout flare) or outpatient setting (to
address issues of adherence). Due to the complexity of inpa-
tient medication reconciliation through chart abstraction, the
development of this measure for inpatient use was dropped,
and instead the working group focused only on outpatient use.
Measure status. Although M3 was endorsed by the
TFP, it was ranked in a tie for eighth highest by the QMS,
so it did not advance to the field testing, implementation
in RISE, or NQF submission stages.
Serum urate monitoring and management
Measure 4: sUA surveillance after start or change in ULT
(TFP, QMS endorsed, RISE incorporated). “IF a patient
with gout starts on or changes ULT, THEN serum urate
should be measured within 6 months after dose change,
BECAUSE serum urate levels are necessary to optimize
ULT management.”
M4 focuses on patients newly started on ULT or with
recent ULT change. In order to adhere to treat-to-target
guidelines, sUA should be checked within 6 months of
dose start or dose change. This measure builds upon a prior
measure concept proposed by other clinical experts (24).
Measure status. M4 was ranked highly with global rating
8.6 (on 1–9 scale) and supported by the QMS for field testing,
implementation in RISE, and submission to the NQF. The
measure performed well in field testing, with 85% agreement
(j = 0.74) between the automated EHR and physician chart
abstraction. At the clinical sites, for the 197 patients meeting
the denominator specification (new ULT start or dose
change), 56% met the QM specification (sUA was checked
within 6 months). From 1,383 patients meeting the
denominator specification in RISE, 33% met the QM
specification. Concern was raised from the clinical sites that
accurate attribution for the date of a ULT dose change was
difficult to abstract. The measure did not receive NQF
endorsement, as NQF panel members expressed concerns
about the use of intermediary biomarkers as quality measure-
ment targets, citing unfavorable outcomes from treat-to-target
trials in dyslipidemia (48) and diabetes mellitus (49).
Measure 5: sUA surveillance for patients with ongoing
symptoms or tophi (TFP endorsed). “IF a patient with
gout has persistent tophus/tophi or 2 or more attacks per
year, THEN serum urate should be measured at least every 6
months, BECAUSE optimal serum urate control is necessary
to reduce gouty flares and decrease tophaceous deposits.”
M5 recommends regular monitoring (sUA every 6 months)
for patients with active gouty symptoms or tophi.
Measure status. This measure was ranked fifth highest,
falling short of recommendation by the QMS for field
testing, incorporation in RISE, or NQF submission. The
subcommittee felt that implementation of other QMs had
greater potential to impact patient care.
Measure 6: optimize ULT (TFP endorsed). “IF a pa-
tient with gout has persistent tophus/tophi or 2 or more
attacks per year AND serum urate ≥6.8 mg/dl, THEN
ULT management should optimized, BECAUSE opti-
mization of ULT management will improve serum urate
levels, decrease the risk for recurrent attacks, and reduce
tophus deposition.”
Measuring sUA is necessary, but insufficient indepen-
dently, to improve gout quality of care. Therefore, M6 was
designed to encourage a change in management for patients
with either tophus or active gout (2 or more attacks per
year) whose sUA is ≥6.8 mg/dl.
Measure status. M6 was supported by the TFP, but it was
noted that “optimization” could mean anything from ULT
dose change or drug change, to patient education or adher-
ence review, or addressing other causes of hyperuricemia
(such as discontinuing thiazides, reinforcing diet, etc.). Due
to concerns that “optimization” was vague, resulting in fea-
sibility concerns, it was ranked sixth highest and, therefore,
not supported by the QMS for further development.
Measure 7: sUA surveillance for all patients on ULT,
regardless of symptoms (TFP endorsed, see combined
M7/8). “IF a patient with gout is receiving ULT, THEN
serum urate should be measured at least once every 12
months, BECAUSE serum urate levels are necessary to
optimize ULT management.” M7 defines the maximum
duration between sUA laboratory testing (12 months) for
any gout patient on ULT.
Measure status. M7 was ranked highly (mean rating 8.1).
To create as parsimonious a list of measures as possible, the
QMS voted to combine M7 with M8 and push the combined
measures forward for field testing, incorporation in RISE, and
submission to NQF. The NQF endorsed the combined eCQM
for eMeasure Trial Approval (see additional details below).
Measure 8: sUA target for all patients on ULT (TFP en-
dorsed, see combined M7/8). “IF a patient with gout has
been treated with ULT for at least 12 months, THEN serum
urate should be less than 6.8 mg/dl, BECAUSE adequate
control of serum urate is needed to reduce acute gouty
attacks and reduce tophus size.”
The conservative sUA target advocated by international
organizations is <6 mg/dl, while some situations and guide-
lines argue for <5 mg/dl (14–16,18). eCQMs are meant to
define a minimum threshold of care for most patients (with
some exceptions), and, therefore, an eCQM threshold
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(minimum level of quality care) is typically more lenient
than clinical guideline statements (optimal level of care).
For example, for patients with diabetes mellitus, the NQF
measure addressing glycosylated hemoglobin (HbA1c)
(NQF-0575) “. . .looks at the percent of patients whose most
recent HbA1c level is less than 8.0% during the measure-
ment year” (50), recognizing that treatment guidelines may
advocate the achievement of even lower HbA1c goals in
practice.
For patients with continued gout symptoms, it is clear
that the treatment target ought to be <6 mg/dl (or lower).
For patients in symptomatic remission (but still on ULT), a
less stringent criterion could be clinically reasonable.
Recent research has begun to question whether ULT can be
safely discontinued in some patients whose sUA remains
<7 mg/dl (off ULT) (51). In this observational cohort, of the
27 patients with sUA remaining <7 mg/dl, no patient was
found to have a clinical gout attack during the median 2
years of followup off ULT. However, frequency of gout
attacks rose quickly with higher sUA levels off ULT.
The working group ultimately selected the solubility con-
centration of urate (6.8 mg/dl) (52) as a physiologically
sound but less stringent threshold for quality measurement
purposes. The working group reinforced that for patients
with symptomatic gout or tophi, sUA <6 mg/dl (or lower)
ought to be the goal, but did not want to penalize clinicians
whose patients might be in clinical remission with sUAs
that might be slightly higher than 6 mg/dl.
With a vibrant internal debate about the precise threshold
to specify, this eCQM was initially ranked lowest by the
TFP (mean rating 6.3), with some members ranking the
eCQM very low, voicing concern against promulgating a
treatment target >6.0 mg/dl that did not directly align with
the ACR gout guideline recommendations. Despite this con-
troversy, the QMS felt that this eCQM was the key compo-
nent of the overall treat-to-target strategy emphasized in the
2012 ACR gout guidelines, and therefore this eCQM was
advanced to testing by the QMS after combining it with M7.
Measure 7/8: treat-to-target (QMS, NQF endorsed, RISE
incorporated). “IF a patient with gout has been treated
with ULT for at least 12 months, THEN serum urate should
be checked at least once yearly AND be <6.8 mg/dl,
BECAUSE adequate control of serum urate is needed to
reduce acute gouty attacks and reduce tophus size.”
The QMS combined M7 and M8 to create a new eCQM.
M8 (sUA <6.8 mg/dl) is conditional on sUA being checked,
as noted in M7 (annual sUA monitoring for all patients on
ULT). However, NQF limits the number of QMs to be
approved, and the QMS was concerned about the number
of QMs to be submitted; if both measures were not
approved then M8 would not address patients where sUA
was not checked, a frequent occurrence (72% of patients in
a managed care study [43] and 85–90% of patients in an
international study [42]). The combined measure (M7/8)
was recommended for field testing and NQF submission,
and subsequently received NQF eMeasure Trial Approval.
The measure is easy to abstract, simply requiring identifi-
cation of gout patients on ULT and then evaluating labora-
tory results. At the validation sites, the measure performed
well, with 96% agreement (j = 0.92). Of the 171 patients
identified on ULT at the validation sites, 54% had a recent
sUA <6.8 mg/dl. From RISE, of the 1,929 gout patients iden-
tified on ULT, 32% had a recent sUA <6.8 mg/dl.
Allopurinol-specific considerations
Measure 9: allopurinol starting dose (TFP endorsed).
“IF a patient is newly started on allopurinol, THEN the
starting dose should be less than 300 mg/day (stricter dose
limitations required for patients with renal disease [e.g., for
patients with chronic kidney disease (CKD) ≥4 (glomerular
filtration rate <30 ml/minute)], THEN, the starting dose of
allopurinol should be ≤50 mg per day), BECAUSE this
strategy may reduce risk of early gout flares and reduce the
risk of hypersensitivity reactions.
Allopurinol is by far the most commonly prescribed ULT
and deserving of special attention. The 2012 ACR gout guide-
lines recommend starting all patients at 100 mg/day (lower in
the presence of significant renal dysfunction). Public feedback
included comments noting that 150 mg/day is a commonly
prescribed and patient-friendly dose (as 300-mg pills can be
split into 150-mg halves), consistent with the intent of the
guideline recommendations. Therefore, the eCQM allopurinol
starting dose specification was modified to <300 mg/day, and
≤50 mg/day for those with CKD ≥4 or end-stage renal disease.
This change was again consistent with the desire to generate
QMs that prioritize minimal standards as compared to best
practices promoted in treatment guidelines.
Measure status. This measure, although endorsed by the
TFP, was ranked seventh highest by the QMS, which was
insufficient to gain support for field testing, inclusion in
RISE, or submission to the NQF.
Gout flare prophylaxis
Measure 10: gout flare prophylaxis (TFP, QMS en-
dorsed). “IF a patient with gout is initiated on ULT, THEN
antiinflammatory prophylaxis should be used concomitantly
consisting of low-dose colchicine, nonsteroidal antiinflam-
matory drugs (NSAIDs), or glucocorticoid, BECAUSE con-
comitant use of prophylaxis reduces the risk of gout flares.”
The use of prophylactic antiinflammatory agents with
ULT is seen as crucial because gout flares are among the
most common complications of ULT, particularly poorly
managed ULT, and their occurrence may jeopardize
Table 4. Number of gout patients meeting the
denominator definition at the clinical testing sites and
in the RISE registry, respectively, and the proportion
(in parentheses) that passed each of the eCQM.
Clinical
testing sites RISE
M2: ULT indications 96 (58) 515 (56)
M4: Serum urate monitoring 197 (56) 1,383 (33)
M7/8: Serum urate target 171 (54) 1,929 (32)
* RISE = Rheumatology Informatics System for Effectiveness;
eCQM = electronically specified clinical quality measure; ULT =
urate-lowering therapy.
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adherence to otherwise highly effective treatments. The
ACR gout guidelines recommended that pharmacologic
antiinflammatory prophylaxis be used in all cases of gout
where ULT is initiated (53).
Measure status. This measure was ranked highly, sup-
ported by the QMS, and recommended for field testing,
incorporation into RISE, and NQF submission. Significant
practical concerns about defining and capturing use of low-
dose NSAIDs (potentially over the counter) and concerns
about prolonged steroid use led to its failure to receive NQF
endorsement. Though supported by the QMS, given the
above feasibility concerns, field-testing and incorporation
into RISE was not done.
Clinical testing and validation
As described above, 3 eCQMs (M2, M4, andM7/8) were incor-
porated into RISE for use by ACR members; Table 2 contains
more specific denominator, numerator, and exclusion defini-
tions for these measures. The results of field testing, including
validation against medical record data, are provided in
Tables 3 and 4. All electronically abstracted eCQMs demon-
strated good validity with kappa values ≥0.74 when compared
to physician-abstracted clinical data. The measure perfor-
mance across the 3 field-testing sites ranged from 54–58% for
the 3 measures, while initial performance results in RISE
demonstrated a range of performance of 32–56% for the 3 mea-
sures, supporting room for improvement even among highly
motivated rheumatology practices (Table 4).
DISCUSSION
Gout is often poorly managed, as noted above. Given the
prevalence and growing public health burden posed by
gout, along with the availability of relatively inexpensive
but highly effective interventions, better treatment of gout
should lead to meaningful improvements in patient quality
of life and savings to the health care system. We have devel-
oped, tested, and gained preliminary NQF support of 2
eCQMs intended to improve the care of patients with gout.
These represent a first step, beyond clinical guidelines,
toward improving provider performance through measure-
ment. They are valid, reliable, and electronically specified
measures that have been implemented in a national registry
and, as such, can immediately begin to support local prac-
tice improvement efforts, as well as potentially be imple-
mented in federal reporting programs in the future.
Two of 4 measures submitted to NQF were given eMea-
sure Trial Approval as eCQMs. This is a new category of
NQF endorsement focused on measures specifically devel-
oped and tested for use with EHRs. These eCQM undergo
the same NQF scrutiny and evaluation as traditional QMs,
with the following endorsement criteria: 1) importance to
measure and report, 2) scientific acceptability of measure
properties, 3) usability and use, and 4) related and compet-
ing measures. The ACR gout eCQMs were the first eCQMs
to be reviewed by NQF in this category. The 2 eCQMs (M2
and M7/8) that received the time-limited endorsement as
eMeasures from NQF will be re-submitted to NQF for full
endorsement based on the supporting reliability data gener-
ated from clinical site testing (54).
The purpose of treatment guidelines is to serve as a resource
when managing a variety of case scenarios in gout, whereas
QMs serve as benchmarks for evaluation of standardized
patient care to improve patient outcomes. QMs also serve as
an opportunity for providers to benchmark their own perfor-
mance against their peers, providing critical information for
improving care and thus patient outcomes. The expansion of
EHRs that can report QMs provides an opportunity to assess a
wide range of clinical care. Such performance measures can
assess health care structures, processes, outcomes, and patient
perceptions of care. These standards can be used by institu-
tions, providers, and health care consumers to 1) create reli-
able, comparative performance information to make informed
decisions about their care, 2) ensure that providers are held
accountable for the quality and efficiency of their perfor-
mance, and 3) support future quality improvement activities.
No measure is perfect, and all measures have limitations.
Each measure is developed with the goal of creating a tool
that promotes transparency where there is obscurity, and to
balance the challenges and burden of collecting data with
providing sufficient detail for validity. As such, quality mea-
surement is not without its controversies.
The ACP Clinical Guidelines Committee recently chal-
lenged the “treat-to-target” strategy, arguing for “treat-to-
avoid-symptoms” in its place (55). They chose to adhere
to a stricter interpretation of Institute of Medicine guid-
ance on guideline development (56), favoring treating to
avoid symptoms over treating to an intermediary target
(57). However, several editorials pointed out concerns
with the ACP position, including limited evidence to
support a “treat-to-avoid-symptoms” approach (58,59).
The QMs put forth in this document are based upon evi-
dence-based guidelines with extensive clinical expert
input, and specific QMs (including the “treat-to-target”
QM) have been tested and vetted by the NQF. The ACR
rationale for more directive guidelines is supported by a
recent Journal of the American Medical Association
viewpoint, where the authors argue that “. . .the purpose
of practice guidelines must be to develop the best possi-
ble recommendations from a body of evidence that may
be contradictory or inadequate. Because patient care
requires action, treating physicians require guidance.
Recommendations in practice guidelines should, there-
fore, define a standard of care for physicians who must
act in the absence of evidentiary certainty. It should be
acknowledged that the recommendations in guidelines
may change as new data become available, but those rec-
ommendations should always represent the best evi-
dence and the best expert opinion currently available”
(60). After a decade of gout guideline development with-
out measuring physician performance, data support that
a significant performance gap continues to exist (61).
Continued absence of measurement will not improve this
situation.
Gout is a common clinical disease resulting in pain, dis-
ability, decreased quality of life, and excess health care
costs. QMs to provide information about what care is being
provided to patients and how providers can improve their
care to optimize patient outcomes are badly needed. It is
our hope that implementation of these QMs may con-
tribute to meaningful improvement in the quality of gout
ACR Electronic Clinical Quality Measures for Gout 669
care by providing a tool for benchmarking providers and
institutions. Followup studies will be needed to evaluate
the impact of implementing gout QMs on patient out-
comes.
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